natgillin/translations-raw huggingface dataset:
Concomitant use of colchicine and darunavir coadministered with low dose ritonavir may increase the exposure to colchicine. 
Istodobna primjena kolhicina i darunavira primijenjenog istodobno s niskom dozom ritonavira može povećati izloženost kolhicinu. (inhibicija CYP3A i/ili P-gp-a)
Co administration of boosted darunavir with clonazepam may increase concentrations of clonazepam. 
Istovremena primjena pojačanog darunavira s klonazepamom može povećati koncentracije klonazepama. (CYP3A inhibicija)
Each film-coated tablet contains 400 mg of darunavir. 
Jedna filmom obložena tableta sadrži 400 mg darunavira.
Each film-coated tablet contains 300 mg of darunavir. 
Jedna filmom obložena tableta sadrži 300 mg darunavira.
The recommended dose regimen is 800 mg once daily with cobicistat 150 mg once daily or ritonavir 100 mg once daily taken with food. 
Preporučeni režim doziranja je 800 mg jedanput na dan s ritonavirom od 100 mg jedanput na dan uzeto s hranom.
The Summary of Product Characteristics of ritonavir must, therefore, be consulted prior to initiation of therapy with darunavir. 
Stoga se, prije početka terapije lijekom darunavir, mora pročitati Sažetak opisa svojstava lijeka za ritonavir.
Darunavir Mylan 600 mg film-coated tablets Each film-coated tablet contains 600 mg of darunavir. 
Darunavir Mylan 600 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 600 mg darunavira.
- In the morning, take 600 milligram darunavir together with 100 milligram ritonavir. 
- Ujutro uzmite uzmite 600 miligrama darunavira zajedno sa 100 miligrama ritonavira.
Pharmacokinetic results of total darunavir after administration of darunavir/ritonavir at 800/100 mg once daily as part of an antiretroviral regimen, during the second trimester of pregnancy, the third trimester of pregnancy and postpartum 
Farmakokinetički rezultati ukupnog darunavira nakon primjene darunavira/ritonavira 800/100 mg jedanput dnevno kao dijela antiretrovirusnog režima liječenja tijekom drugog trimestra trudnoće, trećeg trimestra trudnoće i postpartalnog razdoblja Farmakokinetika ukupnog darunavira (srednja vrijednost ± SD)
White to off-white, oval shaped, biconvex film-coated tablets approximately 9.7 mm by 4.6 mm, debossed with ‘M' on one side and ‘DV1' on the other side. 
Bijela do gotovo bijela, ovalna, bikonveksna filmom obložena tableta približne veličine 9,7 mm × 4,6 mm s utisnutom oznakom „M” na jednoj strani i „DV1” na drugoj strani.
tenofovir AUC ↑ 22% tenofovir Cmin ↑ 37% tenofovir Cmax ↑ 24% #darunavir AUC ↑ 21% 
tenofovir AUC ↑ 22% tenofovir Cmin ↑ 37% tenofovir Cmax ↑ 24% darunavir AUC ↑ 21% #darunavir Cmin ↑ 24% #darunavir Cmax ↑ 16% (↑tenofovira zbog učinka na transport putem MDR-1 u bubrežnim tubulima)
Co-administration of darunavir with low dose ritonavir and alfuzosin is contraindicated (see section 4.3). 
Istodobna primjena darunavira s niskom dozom ritonavira i alfuzozina je kontraindicirana (vidjeti dio 4.3).
Characteristics of ritonavir as appropriate, must therefore be consulted prior to initiation of therapy with darunavir. 
Stoga se, prije početka terapije darunavirom, mora pročitati odgovarajući Sažetak opisa svojstava lijeka za ritonavir.
Darunavir Mylan 600 mg film-coated tablets are available in blister packs containing 30 and 60 tablets and in plastic bottles containing 30, 60 and 90 tablets. 
Darunavir Mylan 600 mg filmom obložene tablete dostupne su u blister pakiranjima koja sadržavaju 30 i 60 tableta i plastičnim bocama koje sadržavaju 30, 60 i 90 tableta.
Efficacy of darunavir 800 mg once daily co-administered with 150 mg cobicistat once daily in ART-naïve and ART-experienced patients 
Djelotvornost darunavira od 800 mg jedanput na dan primijenjenog istodobno sa 150 mg kobicistata jedanput na dan u bolesnika prethodno neliječenih ART-om i u bolesnika prethodno liječenih ART-om
Darunavir Mylan 400 mg film-coated tablets EU/1/16/1140/022 
Darunavir Mylan 400 mg filmom obložene tablete EU/1/16/1140/022
The pharmacokinetics of darunavir in combination with ritonavir taken once daily in 10 treatmentexperienced paediatric patients, aged 3 to < 6 years and weighing at least 14 kg to < 20 kg, showed that weight-based dosages resulted in darunavir exposure that was comparable to that achieved in adults receiving darunavir/ritonavir 800/100 mg once daily (see section 4.2). 
Farmakokinetika darunavira u kombinaciji s ritonavirom uzetih jedanput na dan, kod 10 pedijatrijskih prethodno liječenih bolesnika, u dobi od 3 do < 6 godina i težine najmanje 14 kg do < 20 kg, pokazala je da je doziranje temeljeno na težini rezultiralo izloženošću darunaviru, sličnoj onoj postignutoj u odraslih koji su uzimali darunavir/ritonavir 800/100 mg jedanput na dan (vidjeti dio 4.2).
Treatment-naïve darunavir/cobicistat 800/150 mg once daily N=295 
Prethodno nisu liječeni darunavir/kobicistat 800/150 mg jedanput na dan N=295
Twice daily dosing 
Doziranje dva puta na dan Težina
Rare thrombocytopenia, neutropenia, anaemia, leucopenia increased eosinophil count 
Poremećaji krvi i limfnog sustava manje često rijetko trombocitopenija, neutropenija, anemija, leukopenija povišen broj eozinofila
Otherc mean CD4+ cell count change from baseline (x 10 
Srednja vrijednost promjene broja CD4+ stanica u odnosu na početni (x 10
For further information on cobicistat, consult the cobicistat Summary of Product Characteristics. 
Za daljnje informacije o kobicistatu, pogledajte Sažetak opisa svojstava lijeka za kobicistat.
Darunavir Mylan 800 mg film-coated tablets EU/1/16/1140/039 
Darunavir Mylan 800 mg filmom obložene tablete EU/1/16/1140/039
Darunavir is expected to increase these antineoplastic plasma concentrations. 
Očekuje se da će darunavir povećati koncentracije tih antineoplastika u plazmi. (CYP3A inhibicija)
Hence, concomitant use of darunavir co-administered with low dose ritonavir and the combination product lopinavir/ritonavir is contraindicated (see section 4.3). 
Odavde proizlazi da je istodobna primjena darunavira s niskom dozom ritonavira i kombiniranog lopinavira/ritonavira kontraindicirana (vidjeti dio 4.3).
Darunavir/ritonavir 800/100 mg once daily + OBR N=294 
Darunavir/ritonavir 800/100 mg jedanput na dan + OOR n=294
Darunavir Mylan 150 mg film-coated tablets darunavir 
Darunavir Mylan 150 mg filmom obložene tablete darunavir
Darunavir Mylan 300 mg film-coated tablets EU/1/16/1140/012 
Darunavir Mylan 300 mg filmom obložene tablete EU/1/16/1140/012
White to off-white, oval shaped, biconvex film-coated tablets approximately 19.2 mm by 9.6 mm, debossed with ‘M' on one side and ‘DV4' on the other side. 
Bijela do gotovo bijela, ovalna, bikonveksna filmom obložena tableta približne veličine 19,2 mm × 9,6 mm s utisnutom oznakom „M” na jednoj strani i „DV4” na drugoj strani.
Darunavir co-administered with cobicistat should not be used in combination with another antiretroviral agent that requires pharmacoenhancement by means of co saquinavir/darunavir/ritonavir1,000/400/100 mg twice daily Darunavir: comparison of darunavir/ritonavir 400/100 mg twice daily vs. darunavir/ritonavir 400/100 mg in combination with saquinavir 1,000 mg twice daily. 
Sakvinavir: usporedba sakvinavir/ritonavir 1000/100 mg dva puta na dan naspram sakvinavir/darunavir/ritonavir 1000/400/100 mg dva puta na dan Darunavir: usporedba darunavir/ritonavir 400/100 mg dva puta na dan naspram darunavir/ritonavir 400/100 mg u kombinaciji sa sakvinavirom 1000 mg dva puta na dan.
Number of subjects with virologic failure and paired baseline/endpoint phenotypes, showing loss of susceptibility to PIs at endpoint compared to baseline, n/N PI darunavir amprenavir atazanavir indinavir lopinavir saquinavir tipranavir a TLOVR non-VF censored algorithm based on HIV-1 RNA < 50 copies/ml, except for TITAN (HIV-1 RNA < 
Broj ispitanika s virološkim neuspjehom i spareni genotip na početku/na kraju liječenja, koji su razvili mutacije b na ishodu ispitivanja, n/N Primarne (velike) IP mutacije IP RAM Broj ispitanika s virološkim neuspjehom i odgovarajući fenotip na početku/na kraju liječenja koji pokazuju gubitak osjetljivosti na IP na ishodu u usporedbi s onim na početku liječenja, n/N
Darunavir Mylan 800 mg film-coated tablets 
Darunavir Mylan 800 mg filmom obložene tablete
White to off-white, oval shaped, biconvex film-coated tablets approximately 21.2 mm by 10.6 mm, debossed with ‘M' on one side and ‘DV8' on the other side. 
Bijela do gotovo bijela, ovalna, bikonveksna filmom obložena tableta približne veličine 21,2 mm × 10,6 mm s utisnutom oznakom „M” na jednoj strani i „DV8” na drugoj strani.
Darunavir Mylan 600 mg film-coated tablets EU/1/16/1140/030 
Darunavir Mylan 600 mg filmom obložene tablete EU/1/16/1140/030
White to off-white, oval shaped, biconvex film-coated tablets approximately 21.2 mm by 10.6 mm, debossed with ‘M' on one side and ‘DV5' on the other side. 
Bijela do gotovo bijela, ovalna, bikonveksna filmom obložena tableta približne veličine 21,2 mm × 10,6 mm s utisnutom oznakom „M” na jednoj strani i „DV5” na drugoj strani.
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with darunavir co-administered with low dose ritonavir is required. 
Ako je potrebno liječenje darunavirom istodobno primijenjenim s niskom dozom ritonavira, preporučuje se smanjiti dozu kolhicina ili prekinuti liječenje kolhicinom u bolesnika s normalnom funkcijom bubrega ili jetre.
Darunavir Mylan 150 mg film-coated tablets are white to off-white, capsule shaped, with two curved sides, marked with M on one side and DV2 on the other side. 
Darunavir Mylan 150 mg filmom obložene tablete bijele su do gotovo bijele boje, duguljastog oblika s dvije zaobljene stranice i označene su s M na jednoj strani i DV2 na drugoj strani.
ART-naïve paediatric patients (3 to 17 years of age and weighing at least 40 kg) The recommended dose regimen is 800 mg once daily with ritonavir 100 mg once daily taken with food. 
Odrasli bolesnici koji nisu prethodno liječeni antiretrovirusnom terapijom (ART-om) Preporučeni režim doziranja je 800 mg jedanput na dan uz 150 mg kobicistata jedanput na dan ili 100 mg ritonavira jedanput na dan uzeto s hranom.
Darunavir Mylan 800 mg film-coated tablets are white to off-white, oval shaped, with two curved sides, marked with M on one side and DV8 on the other side. 
Darunavir Mylan 800 mg filmom obložene tablete bijele su do gotovo bijele boje, ovalnog oblika s dvije zaobljene strane i označene su s M na jednoj strani i DV8 na drugoj strani.
For information on cobicistat, consult the cobicistat Summary of Product Characteristics. 
Za informacije o kobicistatu, pročitajte Sažetak opisa svojstava lijeka za kobicistat.
Treatment-naïve darunavir/cobicistat 800/150 mg once daily + OBR N=295 
Prethodno ne liječeni darunavir/kobicistat 800/150 mg jedanput na dan+ OOR N=295
Darunavir Mylan 300 mg film-coated tablets 
Darunavir Mylan 300 mg filmom obložene tablete
The pharmacokinetics of darunavir in combination with ritonavir taken twice daily in 14 treatmentexperienced paediatric patients, aged 3 to < 6 years and weighing at least 15 kg to < 20 kg, showed that weight-based dosages resulted in darunavir exposure that was comparable to that achieved in adults receiving darunavir/ritonavir 600/100 mg twice daily (see section 4.2). 
Farmakokinetika darunavira u kombinaciji s ritonavirom uzetih dva puta na dan, kod 14 prethodno liječenih pedijatrijskih bolesnika u dobi 3 do < 6 godina s težinom najmanje 15 kg do < 20 kg, pokazala je da doziranje ovisno o tjelesnoj težini rezultira izloženošću darunaviru koja je usporediva s onom kod odraslih koji primaju darunavir/ritonavir od 600/100 mg dva puta na dan (vidjeti dio 4.2).
problems with your balance - difficulty breathing, cough, nosebleed, throat irritation - inflammation of the stomach or mouth, heartburn, retching, dry mouth, discomfort of the abdomen, constipation, belching - kidney failure, kidney stones, difficult discharge of urine, frequent or excessive passage of urine, sometimes at night 
problemi s ravnotežom - otežano disanje, kašalj, krvarenje iz nosa, nadraženost grla - upala želuca ili ustiju, žgaravica, dizanje želuca, suha usta, nelagoda u trbuhu, zatvor,
Co-administration with darunavir coadministered with cobicistat is not recommended (see section 4.4). 
Ne preporučuje se istodobna primjena s darunavirom istodobno primijenjenim s kobicistatom (vidjeti dio 4.4).
darunavir/ ritonavir 800/100 mg once daily N=294 
Darunavir/ ritonavir 800/100 mg jedanput na dan n=294
Concomitant use of darunavir with low dose ritonavir and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) 
Istodobna upotreba darunavira s niskom dozom ritonavira i kortikosteroida koje metabolizira CYP3A (npr. flutikazon propionat ili ostali inhalacijski ili nazalni kortikosteroidi) može povećati opasnost od razvoja sistemskih učinaka kortikosteroida uključujući Cushingov sindrom i adrenalnu supresiju.
When administration of rosuvastatin and boosted darunavir is required, it is recommended to start with the lowest possible dose of rosuvastatin and titrate up to the desired clinical effect while monitoring for safety. 
Kada je potrebno primijeniti rosuvastatin i pojačani darunavir, preporučuje se početi s najnižom mogućom dozom rosuvastatina te dozu titrirati do željenog kliničkog učinka i pri tome pratiti sigurnost primjene.
When administration of rosuvastatin and darunavir coadministered with low dose ritonavir is required, it is recommended to start with the lowest possible dose of rosuvastatin and titrate up to the desired clinical effect while monitoring for safety. 
Kada je potrebno primijeniti rosuvastatin i darunavir primijenjen istodobno s niskom dozom ritonavira, preporučuje se početi s najnižom mogućom dozom rosuvastatina te dozu titrirati do željenog kliničkog učinka i pri tome pratiti sigurnost primjene.
Indinavir: comparison of indinavir/ritonavir 800/100 mg twice daily vs. indinavir/darunavir/ritonavir 800/400/100 mg twice daily. 
Indinavir: usporedba indinavir/ritonavir 800/100 mg dva puta na dan vs. indinavir/darunavir/ritonavir 800/400/100 mg dva puta na dan Darunavir: usporedba darunavir/ritonavir 400/100 mg dva puta na dan vs. darunavir/ritonavir 400/100 mg u kombinaciji s indinavirom 800 mg dva puta na dan.
White to off-white, oval shaped, biconvex film coated tablets approximately 16.5 mm by 8.2 mm, debossed with 'M' on one side of the tablet and 'DV3' on other side. 
Bijela do gotovo bijela, ovalna, bikonveksna filmom obložena tableta približne veličine 16,5 mm × 8,2 mm s utisnutom oznakom „M” na jednoj strani i „DV3” na drugoj strani.
darunavir/ ritonavir 600/100 mg twice daily N=298 
Darunavir/ ritonavir 600/100 mg dva puta na dan n=298
Darunavir Mylan 400 mg film-coated tablets are available blister packs containing 30 and 60 tablets and in the HDPE bottles of 60 and 100 tablets. 
Darunavir Mylan 400 mg filmom obložene tablete dostupne su u blister pakiranjima koja sadržavaju 30 i 60 tableta i plastičnim bocama koje sadržavaju 60 i 100 tableta.
Darunavir Mylan 800 mg film-coated tablets darunavir 
Darunavir Mylan 800 mg filmom obložene tablete darunavir
Name and address of the manufacturers responsible for batch release 
PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U PROMET Nazivi i adrese proizvođača odgovornih za puštanje serije lijeka u promet Mylan Hungary Kft
- In the evening, take one 600 milligram darunavir tablet together with 100 milligram ritonavir. 
- Navečer uzmite jednu tabletu darunavira od 600 miligrama zajedno sa 100 miligrama ritonavira.
- In the morning, take one 600 milligram darunavir tablet together with 100 milligram ritonavir. 
- Ujutro uzmite jednu tabletu darunavira od 600 miligrama zajedno sa 100 miligrama ritonavira.
Darunavir/ ritonavir 600/100 mg twice daily N=296 
Darunavir/ ritonavir 600/100 mg dva puta na dan n=296
Darunavir Mylan 400 mg film-coated tablets darunavir 
Darunavir Mylan 400 mg filmom obložene tablete darunavir
Ciclosporin Sirolimus Tacrolimus Everolimus 
Ciklosporin Sirolimus
Darunavir Mylan 600 mg film-coated tablets darunavir 
Darunavir Mylan 600 mg filmom obložene tablete darunavir
Darunavir Mylan 600 mg film-coated tablets are white to off-white, oval shaped, with two curved sides, marked with M on one side and DV5 on the other side. 
Darunavir Mylan 600 mg filmom obložene tablete bijele su do gotovo bijele boje, ovalnog oblika s dvije zaobljene stranice i označene su s M na jednoj strani i DV5 na drugoj strani.
Darunavir/ritonavir 600/100 mg twice daily + OBR N=296 
Darunavir/ritonavir 600/100 mg dva puta na dan + OOR n=296
Boosted darunavir and didanosine can be used without dose adjustments. 
Pojačani darunavir se može primijeniti s didanozinom bez prilagodbe doze.
Darunavir Mylan 300 mg film-coated tablets are white to off-white, oval shaped, with two curved sides, marked with M on one side and DV3 on the other side. 
Darunavir Mylan 300 mg filmom obložene tablete bijele su do gotovo bijele boje, ovalnog oblika s dvije zaobljene stranice i označene su s M na jednoj strani i DV3 na drugoj strani.
When administration of pravastatin and boosted darunavir is required, it is recommended to start with the lowest possible dose of pravastatin and titrate up to the desired clinical effect while monitoring for safety. 
Kada je potrebno primijeniti pravastatin i pojačani darunavir, preporučuje se početi s najnižom mogućom dozom pravastatina te dozu titrirati do željenog kliničkog učinka i pri tome pratiti sigurnost primjene.
(drug) hypersensitivity immune reconstitution inflammatory syndrome 
Upalni sindrom imunološke rekonstitucije
Darunavir Mylan 300 mg film-coated tablets darunavir 
Darunavir Mylan 300 mg filmom obložene tablete darunavir
pravastatin Cmin ND pravastatin Cmax ↑ 63% an up to five-fold increase was seen in a limited subset of subjects 
¶ kod limitirane podskupine ispitanika primijećeno je povišenje do pet puta
Darunavir co-administered with low dose ritonavir and raltegravir can be used without dose adjustments. 
Darunavir istodobno primijenjen s niskom dozom ritonavira i raltegravirom može se primijeniti bez prilagodbe doze.
Efavirenz in combination with darunavir once daily may result in sub-optimal darunavir Cmin. 
Efavirenz u kombinaciji s darunavirom može rezultirati suboptimalnom vrijednošću Cmin darunavira.
Darunavir Mylan 400 mg film-coated tablets are white to off-white, oval shaped with two curved sides, marked with M on one side and DV4 on the other side. 
Darunavir Mylan 400 mg filmom obložene tablete bijele su do gotovo bijele boje, ovalnog oblika s dvije zaobljene stranice i označene su s M na jednoj strani i DV4 na drugoj strani.
Boosted darunavir is expected to increase these β-blocker plasma concentrations. 
Očekuje se da će pojačani darunavir povećati koncentracije tih β-blokatora u plazmi. (CYP2D6 inhibicija)
The recommended dose regimen is 600 mg twice daily taken with ritonavir 100 mg twice daily taken with food. 
Odrasli bolesnici prethodno liječeni antiretrovirusnom terapijom (ART-om) Preporučeni režim doziranja je 600 mg dva puta na dan uz 100 mg ritonavira dva puta na dan uzeto s hranom.
Dose for children 3 years of age and above, weighing more than 40 kilograms who have taken antiretroviral medicines before (your child's doctor will determine this) The dose is either: - 800 milligram darunavir (2 tablets containing 400 milligram of darunavir or 1 tablet containing 
Doza za djecu u dobi od 3 godine i više, težine najmanje 40 kilograma koja su prethodno uzimala antiretrovirusne lijekove (to će odrediti liječnik Vašeg djeteta) Doza može biti: - 800 miligrama darunavira (2 tablete koje sadrže 400 miligrama darunavira ili 1 tableta koja sadrži 800 miligrama darunavira) zajedno sa 100 miligrama ritonavira jedanput na dan.
Darunavir/ritonavir 600/100 mg twice daily + OBR N=298 
Darunavir/ritonavir 600/100 mg dva puta na dan + OOR n=298
375 milligram darunavir + 50 milligram ritonavir twice a day between 30 and 40 kilograms 
Jedna doza je između 15 i 30 kilograma 375 miligrama darunavira + 50 miligrama ritonavira, dva puta na dan između 30 i 40 kilograma 450 miligrama darunavira + 60 miligrama ritonavira, dva puta na dan više od 40 kilograma*
44.1%)c c 
(57; 114)c
If you notice within 12 hours, you must take the tablets immediately. 
Ako primijetite da niste uzeli lijek unutar 12 sati, tablete morate uzeti odmah, uvijek s kobicistatom ili ritonavirom i hranom.
- Take your other HIV medicines used in combination with darunavir and ritonavir as recommended by your doctor. 
- Ostale lijekove protiv HIV-a koje primjenjujete istodobno s darunavirom i ritonavirom,
When administration of pravastatin and darunavir co-administered with low dose ritonavir is required, it is recommended to start with the lowest possible dose of pravastatin and titrate up to the desired clinical effect while monitoring for safety. 
Kada je potrebno primijeniti pravastatin i darunavir primijenjen istodobno s niskom dozom ritonavira, preporučuje se početi s najnižom mogućom dozom pravastatina te dozu titrirati do željenog kliničkog učinka i pri tome pratiti sigurnost primjene.
Recommended dose for treatment-experienced paediatric patients (3 to 17 years) with darunavir tablets and ritonavir a 
Preporučena doza tableta darunavira i ritonavira a za liječenje pedijatrijskih bolesnika (3 do 17 godina) koji nisu prethodno liječeni ART-om Tjelesna težina (kg)
Darunavir Mylan 75 mg film-coated tablets 
Darunavir Mylan 75 mg filmom obložene tablete Filmom obložena tableta.
Not known rash (including macular, maculopapular, papular, erythematous, pruritic rash, generalised rash, and allergic dermatitis) 
Poremećaji kože i potkožnog tkiva vrlo često često rijetko nepoznato osip (uključujući makularni, makulopapularni, papularni, eritematozni, pruritički osip, generalizirani osip i alergijski dermatitis)
The combination of avanafil and boosted darunavir is contraindicated (see section 4.3). 
Kombinacija avanafila i pojačanog darunavira je kontraindicirana (vidjeti dio
Concomitant use of boosted darunavir with lovastatin and simvastatin is therefore contraindicated (see section 
Istodobna primjena pojačanog darunavira s lovastatinom i simvastatinom je zbog toga kontraindicirana (vidjeti dio 4.3).
Boosted darunavir is expected to increase these antineoplastic plasma concentrations. 
Očekuje se da će pojačani darunavir povećati koncentracije tih antineoplastika u plazmi. (CYP3A inhibicija)
ART-experienced paediatric patients (3 to 17 years of age and weighing at least 40 kg) In ART-experienced patients without DRV-RAMs* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10 
U bolesnika prethodno liječenih ART-om koji nemaju DRV RAM*, a imaju plazmatsku HIV 1 RNK < 100 000 kopija/ml i broj CD4+ stanica ≥ 100 stanica x 10
Hepatic impairment 
Mišićno-koštani poremećaji
V.J. 
ili C.
Darunavir/ritonavir 
na temelju objavljenih podataka s darunavirom/ritonavirom
You will require a different dose of darunavir which cannot be administered with these 75 milligram tablets. 
Doza za odrasle koji prije nisu uzimali antiretrovirusne lijekove (to će odrediti Vaš liječnik) Trebat ćete drugačiju dozu darunavira koja se ne može primijeniti tabletama od 75 miligrama.
35 μg/1 mg once daily ethinylestradiol Cmax ↓ 32% β norethindrone AUC ↓ 14% β norethindrone Cmin ↓ 30% β norethindrone Cmax ↔ β β with darunavir/ritonavir based contraceptives are coadministered with darunavir and low dose ritonavir. 
etinilestradiol AUC ↓ 44% β etinilestradiol Cmin ↓ 62% β etinilestradiol Cmax ↓ 32% β noretindron AUC ↓ 14% β noretindron Cmin ↓ 30% β noretindron Cmax ↔ β β s darunavirom/ritonavirom
Darunavir co-administered with low dose ritonavir can be co 
Darunavir primijenjen istodobno s niskom dozom ritonavira može se istodobno primijeniti s antagonistima